

# In-situ forming plga implants for intraocular dexamethasone delivery

C. Bode, Heiko Kranz, Florence Siepmann, Juergen Siepmann

### ► To cite this version:

C. Bode, Heiko Kranz, Florence Siepmann, Juergen Siepmann. In-situ forming plga implants for intraocular dexamethasone delivery. International Journal of Pharmaceutics, 2018, International Journal of Pharmaceutics, 548, pp.337-348. 10.1016/j.ijpharm.2018.07.013 . hal-04467257

## HAL Id: hal-04467257 https://hal.univ-lille.fr/hal-04467257v1


Submitted on 29 Apr 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1	
2	Research article
3	
4	In-situ forming PLGA implants for intraocular dexamethasone delivery
5	
6	C. Bode, <sup>1</sup> H. Kranz, <sup>2</sup> F. Siepmann, <sup>1</sup> J. Siepmann, <sup>1,*</sup>
7	
8	<sup>1</sup> Univ. Lille, Inserm, CHU Lille, U1008, 59000 Lille, France
9	<sup>2</sup> Bayer AG, Muellerstraße 178, 13353 Berlin, Germany
10	
11	
12	
13	
14	
15	
16	
17	*correspondence:
18	Professor Juergen Siepmann, Ph.D.
19	Univ. Lille, College of Pharmacy,
20	INSERM U1008 Controlled Drug Delivery Systems and Biomaterials
21	3, rue du Professeur Laguesse
22	59006 Lille, France
23	Phone: +33-3-20964708
24	juergen.siepmann@univ-lille2.fr
25	

#### 26 Abstract

Different types of *in-situ* forming implants based on poly(lactic-co-glycolic acid) (PLGA) and 27 N-methyl-pyrrolidone (NMP) were prepared for controlled ocular delivery of dexamethasone. 28 The impact of the volume of the release medium, initial drug content, polymer molecular weight 29 and PLGA concentration on the resulting drug release kinetics were studied and explained 30 based on a thorough physico-chemical characterization of the systems. This included for 31 instance the monitoring of dynamic changes in the implants' wet and dry mass, morphology, 32 PLGA polymer molecular weight, pH of the surrounding bulk fluid and water/NMP contents 33 upon exposure to phosphate buffer pH 7.4. Importantly, the systems can be expected to be rather 34 35 robust with respect to variations in the vitreous humor volumes encountered in vivo. Interestingly, limited drug solubility effects within the implants as well as in the surrounding 36 aqueous medium play an important role for the control of drug release at a drug loading of only 37 7.5 %. Furthermore, the polymer molecular weight and PLGA concentration in the liquid 38 formulations are decisive for how the polymer precipitates during solvent exchange and for the 39 swelling behavior of the systems. These features determine the resulting inner system structure 40 and the conditions for mass transport. Consequently, they affect the degradation and drug 41 release of the *in-situ* formed implants. 42



Age-related macular degeneration (AMD) and diabetic retinopathy are two of the leading 46 causes for irreversible blindness and vision impairment (Hughes et al., 2005; Edelhauser et al., 47 2010). Late AMD exists in two forms: the atrophic (or "dry") AMD and the neovascular (or 48 "wet") AMD. Yet, up to now, wet AMD is the only treatable form. It is triggered by vascular 49 endothelial growth factor (VEGF), causing the blood vessels in the retina to grow erratically, 50 eventually breaking through the Bruch's membrane (the innermost layer of the choroid). This 51 52 leads to blood and protein leakage in the macula, resulting in a blurry vision or sudden vision loss (Chiou, 2011; Bonilha et al., 2013). In the case of diabetic retinopathy, microvascular 53 complications are the result of poorly adjusted diabetes. Sustained hyperglycaemia ultimately 54 causes microaneurysms and a breakdown of endothelial tight junctions in the blood-retinal 55 barrier (BRB), allowing proteins to leak into the vitreous. At later stages, choroidal 56 neovascularization of the retina occurs (Kowluru and Mishra, 2015; Wan et al., 2015; Zaki et 57 al., 2016). Both diseases (wet AMD and diabetic retinopathy) are commonly treated by 58 intravitreal injections of anti-VEGF agents and corticosteroids. Anti-VEGF agents inhibit the 59 growth of the blood vessels, while corticosteroids reduce inflammation by minimizing the 60 expression of inflammatory cytokines and of VEGF. Hence, the choroidal neovascularization 61 is stabilized, decreasing the breakdown rate of the blood-retinal barrier (Kurz et al., 2008; 62 Wykoff et al., 2015; Rodríguez Villanueva et al., 2017). 63

For an effective treatment, the drugs have to reach the retina in the back of the eye. However, the anatomy and physiology of the eye hamper this: For instance, when using eye drops, less than 5% of the administered drug is generally absorbed through the cornea to reach the anterior chamber (Urtti, 2006). This is due to the low permeability of the cornea (with its different layers and polarities), dilution with tear fluid, rapid lacrimal drainage and other factors. Most importantly, only a very small fraction of the drug is finally found inside the vitreous: the site of action (approximately 0.001 – 0.0004 % of the administered drug) (Urtti, 2006; Wilson
et al., 2011; Kaur and Kakkar, 2014). It has to be pointed out that systemic drug administration
also encounters a crucial hurdle: The blood-retinal barrier, preventing most drugs from reaching
the vitreous. The attempt to overcome this hurdle with very high systemically administered
drug amounts to achieve therapeutic levels in the eye is limited by severe side effects
(Edelhauser et al., 2010; Kaur and Kakkar, 2014).

For these reasons intravitreal drug injections are currently considered as the most appropriate way to assure that the drug reaches its site of action. However, every injection bears a risk of infections and other serious side effects, like retinal detachment, retinal haemorrhage, endophthalmitis, increased intraocular pressure, cataract or vitreous haemorrhage (Edelhauser et al., 2010; Giudice and Galan, 2012; Ying et al., 2013; Kaur and Kakkar, 2014; Bisht et al., 2017). Apart from these risks, the discomfort of receiving a needle in the eye leads to limited compliance (Droege et al., 2013; Ghazala et al., 2013).

To assure treatment efficacy, therapeutic drug concentrations must be provided over 83 prolonged periods of time at the site of action. Since dexamethasone has a half-life of 84 approximately 5.5 h in the vitreous, frequent injections are, thus, necessary to remain within 85 the therapeutic range (Chan et al., 2011). Local controlled drug delivery systems can help 86 overcoming all these hurdles: The risk of side effects can be reduced, patient compliance 87 improved and the therapeutic efficacy increased. Nowadays, non-biodegradable implants are 88 approved by the FDA for intraocular administration, releasing dexamethasone over prolonged 89 periods of time [e.g., Retisert (retisert.com), Iluvien (iluvien.com)]. However, these implants 90 have to be removed surgically upon drug exhaust, which is associated with similar risks as the 91 initial insertion, or remain in the vitreous where they accumulate over time (Yasin et al., 2014). 92 To avoid the second surgery for device removal, *biodegradable* implants offer an interesting 93 potential. For example, Allergan developed Ozurdex, a biodegradable implant containing 0.7 94

95 mg dexamethasone in a poly(lactic-co-glycolic acid) (PLGA) matrix, which is injected through 96 a 22G needle (Chan et al., 2011). But large needles can be problematic in practice. The injection 97 of a *liquid* solution, that precipitates *in-situ* in the eye and sustains drug release, could 98 effectively reduce the required needle size. Importantly, smaller needles are associated with 99 less pain experienced by the patients (Rodrigues et al., 2011).

Different types of *in-situ* forming implants have been described in the literature, for various 100 types of applications (Kranz and Bodmeier, 2007, 2008; Schoenhammer et al., 2009, 2010; 101 Kempe and Mäder, 2012; Parent et al., 2013, 2017). The transformation from the liquid state 102 (allowing for facilitated administration) to the solid state (allowing for controlled drug release 103 over prolonged periods of time) can be induced by different phenomena, such as solvent 104 exchange, changes in the pH or temperature, or *in-situ* cross-linking (Kempe and Mäder, 2012). 105 In the case of solvent exchange, generally a water-insoluble polymeric matrix former is 106 dissolved in a biocompatible, water-miscible organic solvent. The drug is dissolved and/or 107 dispersed in this polymer solution. Upon injection into aqueous body fluids, the organic solvent 108 diffuses into the surrounding environment (being miscible with water), while water diffuses 109 into the formulation. Since the polymer is water-insoluble, it precipitates and forms the solid 110 implant. The drug molecules or particles are trapped within the implant and slowly released 111 over time. Different formulation parameters can be used to alter implant formation and 112 performance. For instance, the addition of hydrophilic polymers [such as hydroxypropy] 113 methylcellulose (HPMC)] has been proposed to increase the bioadhesion of *in-situ* forming 114 implants releasing antimicrobial drugs in periodontal pockets for the treatment of periodontitis 115 (Do et al., 2014, 2015b, 2015a; Agossa et al., 2017). Poly(lactic-co-glycolic acid) (PLGA) is a 116 well-known biodegradable and biocompatible matrix former in parenteral controlled release 117 formulations (Kranz et al., 2000; Luan et al., 2006; Desai et al., 2008; Kempe et al., 2010; 118 Fredenberg et al., 2011; Ghalanbor et al., 2013; Schwendeman et al., 2014; Gasmi et al., 2015a, 119

2015b; Huang et al., 2015; Gasmi et al., 2016; Hirota et al., 2016; Hamoudi-Ben Yelles et al., 120 2017). In the case of *in-situ* forming implants based on PLGA, often N-methyl-pyrrolidone 121 (NMP) is used as a water-miscible organic solvent, for example in the following commercially 122 available drug products: Atridox (for injection into periodontal pockets) (Thakur et al., 2014); 123 Eligard (for subcutaneous injection) (eligard.com); Nuflor (for intramuscular or subcutaneous 124 injection in beef) (merck-animal-health-usa.com/product/cattle/Nuflor-Injectable-Solution/1); 125 Doxirobe gel (for injection into periodontal pockets dogs) 126 in (zoetisus.com/products/dogs/doxirobe-gel.aspx). Furthermore, the group of AG Mikos (Ueda 127 et al., 2007) reported on NMP-based in-situ forming ocular drug delivery systems for 128 luocinolone acetonide, which are based on poly(propylene fumarate) as polymeric matrix 129 130 former. It has to be pointed out that the toxicity of NMP upon intraocular injection should be investigated in the future. 131

The aim of this study was to prepare different types of *in-situ* forming implants based on PLGA for intraocular dexamethasone delivery. The systems were thoroughly characterized physico-chemically, including for instance dynamic changes in the wet mass, dry mass, water/NMP content, morphology, polymer molecular weight, potential changes in the pH of the release medium, and drug release kinetics.

137

138

#### 139 **2. Materials and methods**

140

#### 141 **2.1. Materials**

Poly(D,L-lactic-co-glycolic acid) (50:50, -COOH end groups; PLGA, Resomer RG 502 H
and Resomer RG 504 H; Evonik, Darmstadt, Germany); dexamethasone (Discovery Fine
Chemicals, Dorset, UK); N-methyl-pyrrolidone, acetonitrile and tetrahydrofuran (Fisher
Scientific, Illkirch, France); ethanol 96% (VWR, Fontenay-sous-Bois, France).

#### 147 **2.2. Preparation of the liquid formulations**

Appropriate amounts of PLGA and dexamethasone were dissolved in NMP in glass vials under stirring at 500 rpm (Multipoint Stirrer, Thermo Scientific, Loughborough, UK) at room temperature for 60 min. Afterwards, the vials were kept without stirring for 1 h at room temperature in order to remove air bubbles. The formulations were stored at 2-8 °C, and allowed to reach room temperature prior to use.

153

#### 154 **2.3.** *In-situ* formation of implants

Eppendorf vials were filled with 2.25 or 4.5 mL phosphate buffer pH 7.4 (USP 40) and kept at 37 °C overnight. One hundred µl of the liquid PLGA/dexamethasone/NMP formulations (prepared as described in *section 2.2.*) were injected into the vials using a syringe pump (2 mL/min; PHD 2000; Harvard Apparatus, Holliston, USA). Solvent exchange initiated polymer precipitation and *in-situ* implant formation. The Eppendorf vials were placed into a horizontal shaker (80 rpm, 37 °C; GFL 3033, Gesellschaft fuer Labortechnik, Burgwedel, Germany).

162

#### 163 2.4. Characterization of *in-situ* formed implants

In vitro drug release: At determined time points, the phosphate buffer pH 7.4 was completely renewed. The amount of dexamethasone in the withdrawn bulk fluid was determined by HPLC-UV analysis, using a Thermo Fisher Scientific Ultimate 3000 Series HPLC, equipped with a LPG 3400 SD/RS pump, an auto sampler (WPS-3000 SL) and a UV-Vis detector (VWD-3400RS) (Thermo Fisher Scientific, Waltham, USA). Samples were centrifuged for 2.5 min at 10,000 rpm (Centrifuge Universal 320; Hettich, Tuttlingen, Germany), and filtered with a 0.45 μm PVDF syringe filter (Millex-HV, Merck Millipore,

Tullagreen, Ireland). Fifty µL samples were injected into an A C18 RP column (Gemini 3 µm 171 C18 110 Å, 100 mm x 4.6 mm; Phenomenex, Le Pecq, France). The mobile phase consisted of 172 acetonitrile and water (33:67 v/v), the flow rate was 1.5 mL/min. Dexamethasone had a 173 retention time of approximately 3.8 min, the detection wavelength was  $\lambda = 254$  nm. The 174 calibration curve was linear (R > 0.999) within the range of 0.06 to 0.00003 mg/mL. To 175 determine the amount of dexamethasone potentially remaining in the implants after 35 d 176 exposure to phosphate buffer pH 7.4, the remnants were freeze-dried for 3 d (Christ Epsilon 2-177 4 LSC; Martin Christ, Osterode, Germany) and the lyophilisates were dissolved in a mixture of 178 acetonitrile and ethanol (2:1 v/v). The solutions were filtered using 0.45 µm PVDF filter 179 syringes, and analyzed for their drug contents by HPLC-UV (as described above). In case of 180 incomplete drug release at the end of the observation period, the "missing" amounts were 181 experimentally recovered in the implant remnants. All experiments were conducted in triplicate. 182 In addition, the pH of the release medium was measured at pre-determined time points using a 183 pH meter (InoLab pH Level 1; WTW, Weilheim, Germany) (n = 3). 184

Implant swelling and erosion: At pre-determined time points, implant samples were withdrawn, excess water carefully removed using Kimtech precision wipes (Kimberly-Clark, Rouen, France) and weighed [*wet mass (t)*]. The samples were lyophilized for 3 d (Christ Epsilon 2–4 LSC) and weighed again [*dry mass (t)*]. The *wet mass (%) (t), water/NMP content* (%) (t), and *dry mass loss (%) (t)* were calculated as follows:

190

wet mass 
$$(\%)(t) = \frac{wet mass(t)}{formulation mass} \times 100\%$$
 (1)

192

193 
$$water/NMP \ content \ (\%)(t) = \frac{wet \ mass \ (t) - dry \ mass(t)}{wet \ mass \ (t)} \times 100 \ \%$$
(2)

194

195  $dry \ mass \ loss \ (\%)(t) = \frac{dry \ mass \ (0) - dry \ mass \ (t)}{dry \ mass \ (0)} \times 100 \ \%$ (3)

where *formulation mass* is the initial total mass of the liquid formulation (PLGA + dexamethasone + NMP), and *dry mass* (0) is the dry mass of the liquid formulation prior to exposure to the release medium (PLGA + dexamethasone). All experiments were conducted in triplicate.

Polymer degradation: At pre-determined time points, implants were withdrawn, freeze-201 dried and the lyophilisates were dissolved in tetrahydrofuran (at a concentration of 3 mg/mL). 202 The average polymer molecular weight (Mw) of the PLGA was determined by Gel Permeation 203 Chromatography (GPC, Separation Modules e2695 and e2695D, 2419 RI Detector, Empower 204 GPC software; Waters, Guyancourt, France) using a PLGel 5 µm MIXED-D column, 7.5 x 205 300 mm (Agilent Technologies, Interchim, Montluçon, France). The injection volume was 206 50 µL. Tetrahydrofuran was the mobile phase (flow rate: 1 mL/min). Polystyrene standards 207 with molecular weights between 1,090 and 70,950 Da (Polymer Labaratories, Varian, Les Ulis, 208 France) were used to prepare the calibration curve. All experiments were conducted in 209 triplicate. 210

Implant morphology: At pre-determined time points, implants were withdrawn and optionally freeze-dried. Cross-sections were obtained by manual breaking. Pictures were taken with an optical image analysis system (Nikon SMZ-U; Nikon, Tokyo, Japan), equipped with a Zeiss camera (AxioCam ICc1; Zeiss, Jena, Germany).

215

#### 216 **2.5. Determination of the drug solubility**

The solubility of dexamethasone (as received) in phosphate buffer pH 7.4 at 37 °C was determined in agitated glass flasks. An excess amount of dexamethasone powder (approximately 30 mg) was exposed to 80 mL bulk fluid, kept at 37 °C under horizontal shaking (80 rpm; GFL 3033). Samples were withdrawn, filtered (0.45 µm PVDF syringe filter), diluted and analyzed for their drug content by HPLC-UV (as described above, using an injection volume of  $20 \,\mu$ L) until equilibrium was reached. Each experiment was conducted in triplicate.

224

#### 225 3. Results and Discussion

226

#### 227 **3.1. Importance of the volume of the release medium**

Since the investigated implants are formed *in-situ* following solvent exchange, it was important to evaluate the impact of the volume of the release medium into which the PLGA/drug/NMP solutions were injected. Potentially, the volume of this aqueous phase can affect the diffusion rate of NMP into the surrounding aqueous phase and/or the diffusion rate of water into the (initially) liquid formulation. Such changes might affect the resulting implant size and inner structure and, hence, the drug release kinetics.

The volume of vitreous humor in humans has been reported to be about 4 to 5 mL (Bennett, 2016). To monitor potential effects of variations in the bulk fluid volume in this order of magnitude on the key properties of the *in-situ* formed implants, 2.25 and 4.5 mL have been investigated in this study. Furthermore, most drugs are eliminated via the anterior pathway (Toris et al., 1999; Urtti, 2006). To simulate drug elimination and fluid renewal, the release medium was completely exchanged every day during the first week (which is most decisive for implant formation) in this study.

Figure 1 shows macroscopic pictures of PLGA-based implants formed upon injection of 100  $\mu$ L of a PLGA/dexamethasone/NMP solution into 2.25 or 4.5 mL phosphate buffer pH 7.4 (37 °C). The liquid formulations contained 30 % Resomer RG 502H and 0.75 % dexamethasone. The photos were taken after 3 d. At the top, implants in Eppendorf tubes (filled with the release medium) are shown. Below, higher magnifications of implants, which had been

carefully withdrawn from the release medium are illustrated (surfaces). At the bottom, surfaces 246 and cross-sections of implant samples after freeze-drying are shown. The cross-sections were 247 obtained by manual breaking. The dashed regions highlight the hollow cores of the implants. 248 As it can be seen, there was no remarkable impact of the volume of the aqueous bulk fluid (2.25 249 vs. 4.5 mL) on the resulting implant morphology: left vs. right hand side in Figure 1. Please 250 note that caution must be paid when drawing conclusions from the pictures of lyophilized 251 implants, because of artifact creation during freeze-drying. Importantly, the implants were 252 hollow also in the wet state (data not shown). This can be explained as follows: Upon contact 253 with water, NMP diffuses into the outer bulk fluid and water diffuses into the liquid NMP 254 formulation. Since PLGA is soluble in NMP, but not in water, at a certain time point the 255 polymer precipitates (once the solubility of the polymer in the water/NMP mixture is reached). 256 This process likely starts at the "formulation – aqueous bulk fluid" interface, because the water 257 concentration is highest and the NMP concentration lowest at this location. The continuous 258 decrease in PLGA solubility in the NMP/water mixture (the NMP content decreases, whereas 259 the water content increases) leads to continued polymer precipitation. Thus, the PLGA "shell" 260 becomes thicker and thicker, growing "inwards". Once all PLGA has precipitated, potentially 261 remaining inner volumes (here the centers of the implants) cannot be filled with polymer and 262 become water-filled cavities. Please note that complete solvent exchange took up to several 263 days in this study: Thus, the implant cores remained liquid for a significant period of time. 264 Importantly, no noteworthy impact of the bulk fluid volume on this cavity formation was 265 observed. 266

Figures 2a and b show the resulting dexamethasone release kinetics and the dynamic changes of the systems' water/NMP contents over time. The water/NMP contents of the implants were determined gravimetrically as the difference between the wet and dry mass of the withdrawn samples (before and after freeze-drying). As it can be seen, the drug release curves were virtually overlapping for the investigated bulk fluid volumes (2.25 vs. 4.5 mL).
Also, the resulting water/NMP contents were very similar. This can probably be attributed to
the fact that NMP and water are freely miscible: So, there are no saturation effects, resulting in
potentially reduced NMP diffusion rates into smaller (eventually more saturated) outer aqueous
phases (and vice versa).

Importantly, limited drug solubility effects in the surrounding release medium are unlikely 276 to affect dexamethasone release from the *in-situ* forming implants at an initial drug loading of 277 0.75 %: The solubility of dexamethasone in phosphate buffer pH 7.4 at 37 °C was determined 278 to be 77  $\pm$  4 µg/mL. In NMP, the drug is freely soluble. Thus, at early time points (when the 279 surrounding bulk fluid contains considerable amounts of NMP) saturation effects in the 280 surrounding bulk fluid are unlikely. Furthermore, even if assuming the absence of any NMP in 281 the surrounding bulk fluid from day 3 on (this is a "worst case scenario" for the drug solubility), 282 sink conditions were also provided for the remaining observation period (considering the drug 283 solubility determined in pure phosphate buffer pH 7.4 at 37 °C). 284

These findings are important, since they demonstrate that variations in the volume of the bulk fluid into which the PLGA/drug/NMP solutions are injected, are not substantially affecting the key properties of the resulting implants. In other words: The proposed *in-situ* forming implant formulations can be expected to be rather robust with respect to variations in the vitreous humor volumes encountered in vivo.

290

#### 291 **3.2. Impact of the drug loading**

Figure 3 shows the impact of the initial drug loading of the *in-situ* forming implant formulations on the resulting dexamethasone release kinetics and the dynamic changes in the implants' wet mass as well as water/NMP contents. The initial drug content was varied from 0.25 to 7.5 %, as indicated. Please note that 100  $\mu$ L of the formulation with the intermediate

drug loading (0.75 %) contain a similar drug dose as the commercially available drug product 296 Ozurdex (0.7 mg) (Chan et al., 2011). The release medium was 2.25 mL phosphate buffer 297 pH 7.4. Resomer RG 502H (30%) was the polymer. Clearly, the relative drug release rates 298 were similar for formulations loaded with 0.25 and 0.75 % dexamethasone (filled and open 299 circles in Figure 2a), whereas the relative drug release rate was substantially lower at 7.5 % 300 drug loading (filled triangles). This cannot be attributed to differences in the dynamic changes 301 in the systems' wet mass, as illustrated in Figure 3b (which were rather similar for all drug 302 loadings). 303

Given the limited solubility of dexamethasone in the release medium (77  $\pm$  4 µg/mL in 304 phosphate buffer pH 7.4 at 37 °C), one hypothesis can be that the substantially reduced drug 305 release rate at 7.5 % initial dexamethasone loading is due to saturation effects. To evaluate the 306 validity of this hypothesis, the renewal rate of the release medium was altered: Figures 4a and 307 b show the resulting drug release kinetics and degrees of bulk fluid saturation (with respect to 308 the drug) observed at a higher and lower sampling frequency (at each sampling time point, the 309 release medium was completely renewed). The degrees of saturation of the release medium 310 were calculated based on the solubility of dexamethasone in phosphate buffer pH 7.4 at 37 °C. 311 Since the surrounding bulk fluid contained important amounts of NMP at early time points, and 312 since dexamethasone is soluble in NMP, no values are indicated in the first week (Figure 4b). 313 Clearly, the higher sampling frequency lead to faster drug release after about 1 week, 314 corresponding to lower degrees of bulk fluid saturation with the drug. Furthermore, after about 315 3 weeks, the degree of bulk fluid saturation substantially decreased (to about 10 % = sink316 conditions) in the case of the higher sampling frequency, while the release rate decreased. These 317 observations indicate that saturation effects likely refer to both: dexamethasone saturation in 318 the surrounding bulk fluid as well as drug saturation effects within the implants: At an initial 319 drug loading of 7.5 %, important parts of the dexamethasone can be expected to precipitate 320

*within* the *in-situ* forming PLGA implants upon water penetration into and NMP leaching out of the system. Consequently, dissolved and non-dissolved dexamethasone co-exist within the implant. It has to be pointed out that only dissolved drug is available for diffusion and can be released into the surrounding bulk fluid (Siepmann and Siepmann, 2012, 2008). Hence, drug release is also likely to be limited by saturation effects *within* the implants.

Please note that during the first week, the observed dexamethasone release rates were very similar for the lower and higher sampling frequency (filled and open circles in Figure 4a). This might be explained by the fact that during this time period noteworthy amounts of NMP were still present *within* the implants and the surrounding bulk fluid (limiting the importance of drug saturation effects).

Furthermore, the initial drug loading had no major impact on the resulting dynamic changes 331 in the implants' wet mass over time (Figure 3b). The latter increased during the first 2.5 weeks, 332 and then decreased again. The initial increase can be attributed to the progressing PLGA 333 degradation and subsequent water penetration into the more and more hydrophilic polymer 334 matrices. The subsequent decrease is likely attributable to the dissolution/disappearance of the 335 remnants (more hydrated regions dissolving faster than less hydrated regions). The water/NMP 336 contents were very high during the observation period, irrespective of the initial drug loading 337 (Figure 3c). 338

339

#### 340 **3.3. Impact of the PLGA polymer molecular weight**

The effects of the polymer molecular weight of the PLGA on drug release and the dynamic changes in the implants' wet mass as well as water/NMP contents upon exposure to phosphate buffer pH 7.4 are illustrated in Figure 5: Resomer RG 502H (Mw about 15 k Da) and Resomer RG 504H (Mw about 45 k Da) are compared. The initial dexamethasone loading was 0.25 %, the polymer concentration in the liquid formulation was 30 %, and the volume of the release

medium was 2.25 mL. As it can be seen, the polymer molecular weight substantially impacted 346 the dynamic changes in the systems' wet mass and water/NMP content: Implants based on 347 longer chain PLGA took up fundamentally less water than systems based on shorter chain 348 PLGA. This can be attributed to the facts that: (i) longer chain PLGA is more hydrophobic than 349 shorter chain PLGA, and (ii) longer chain PLGA is likely to precipitate earlier than shorter 350 chain PLGA upon water penetration into the system and NMP diffusion out of the formulation. 351 The observed differences in the wet mass of the implants based on shorter and longer chain 352 PLGA (Figure 5b) are consistent with the different water/NMP contents of systems (Figure 5c). 353 Whereas the implants based on the more hydrophilic Resomer RG 502H show high water 354 contents right from the beginning, the water contents of Resomer RG 504H-based systems was 355 initially substantially lower, but significantly increased during the observation period (due to 356 the progressive polymer chain cleavage). From a practical point of view, substantial implant 357 swelling should be avoided to minimize any related side effects in vivo. This might for instance 358 be achieved via the selection of appropriate PLGA molecular weights or monomer (lactic acid: 359 glycolic acid) ratios, or specific additives (Do et al., 2014, 2015a,b). 360

Interestingly, these substantial differences in the implants' compositions and water uptake 361 behaviors are "not fully" reflected in the observed release kinetics (Figure 5a). This is because 362 drug release was almost complete within the first few days: the time period of implant 363 formation. For instance, after 4 d only  $3.8 \pm 0.8$  and  $10.5 \pm 1.0$  % dexamethasone remained 364 trapped within the implants based on Resomer RG 502H and Resomer RG 504H, respectively. 365 These amounts were slowly released during the subsequent 3 weeks. The observed slower drug 366 release from Resomer RG 504H-based implants compared to Resomer RG 502H-based 367 implants can at least partially be attributed to the lower water contents of the systems (and, thus, 368 denser polymer networks). Please note that with other drugs, which are not almost completely 369 released within the first few days during implant formation, substantial differences in the 370

resulting release kinetics can be expected from Resomer RG 502H- and Resomer RG 504Hbased implants, due to the fundamentally different conditions for drug release in these systems
(Figures 5b and c).

374

#### 375 **3.4. Impact of the polymer concentration**

Figure 6 shows the observed dexamethasone release kinetics from *in-situ* formed implants 376 prepared with drug-polymer solutions in NMP containing 30 vs. 45% Resomer RG 502H, or 377 15 vs. 30 % Resomer RG 504H. Please note that in the latter case, higher polymer 378 concentrations lead to considerable viscosities, rendering injection difficult. The volume of the 379 release medium was 2.25 mL, the initial drug content 0.25 %. As it can be seen, the polymer 380 concentration in the liquid formulations affected the resulting drug release kinetics, irrespective 381 of the PLGA polymer molecular weight: With increasing polymer concentration the 382 dexamethasone release rate decreased. This can at least partially be attributed to differences in 383 the implants' inner structure, as shown in Figure 7: At the top, cross-sections of freeze-dried 384 implants based on Resomer RG 502H are illustrated, at the bottom cross-sections of implants 385 based on Resomer RG 504H. The implants were lyophilized after 3 d exposure to phosphate 386 buffer pH 7.4. Again, please note that caution should be paid because of potential artifact 387 creation during freeze-drying. The dashed regions indicate the hollow central implant cavities. 388 Clearly, higher polymer concentrations in the liquid formulations lead to smaller cavities. This 389 can be attributed to the fact that PLGA precipitation started at the "liquid formulation – aqueous 390 bulk fluid" interface. Subsequent PLGA precipitation "filled" the in-situ forming implants. In 391 the case of higher polymer concentrations, more polymer was available to fill the interior of the 392 systems, resulting in smaller cavities. The thicker the polymer shells, the longer are the 393 diffusion pathways through the PLGA matrices to be overcome by the trapped drug. Thus, 394

Furthermore, the smaller central implant cavities at higher initial PLGA concentrations 397 resulted in lower increases in the systems' wet mass and lower water contents, irrespective of 398 the PLGA polymer molecular weight (Figures 8 and 9). Figures 10 to 12 illustrate the dynamic 399 changes in the polymer molecular weight (Mw) of the PLGA, the pH of the surrounding bulk 400 fluid and the dry mass loss kinetics of the systems. Importantly, the smaller central implant 401 cavities observed at higher initial polymer concentrations lead to accelerated ester chain 402 cleavage (Figure 10: open symbols always below filled symbols). This can be attributed to an 403 increase in the importance of autocatalytic effects in these systems: Water is present throughout 404 the implants, thus, polymer chain cleavage occurs in the entire polymer matrices. The generated 405 (water-soluble) shorter chain acids slowly diffuse into the surrounding bulk fluid, where they 406 are (at least partially) neutralized. In addition, bases from the surrounding phosphate buffer 407 diffuse into the implants and neutralize (at least partially) the generated acids. However, the 408 rate at which the acids are generated within the implants can be higher than the rate at which 409 they are neutralized. Consequently, the micro-pH can locally drop (Brunner et al., 1999; Ding 410 and Schwendeman, 2004; Li and Schwendeman, 2005; Ding and Schwendeman, 2008; 411 Schädlich et al., 2014), resulting in pH gradients within the implants. Since hydrolytic ester 412 bond cleavage is catalyzed by protons, PLGA degradation is accelerated at locations with low 413 pH values (Grizzi et al., 1995; Lu et al., 1999). The importance of such autocatalytic effects 414 strongly depends on the systems' dimensions and porosity (Siepmann et al., 2005; Klose et al., 415 2006). With increasing polymer concentration in the liquid formulation the thickness of the 416 polymer "shells" increases (Figure 7), hence, autocatalysis is likely more pronounced. The 417 experimentally measured PLGA degradation kinetics shown in Figure 10 clearly confirm this 418 hypothesis: The polymer backbone is more rapidly cleaved at higher PLGA concentrations 419

420 (open vs. filled symbols). Interestingly, this faster PLGA degradation at higher polymer
421 concentrations is not reflected in the drug release kinetics (Figure 6), demonstrating the
422 dominance of the thickness of the PLGA shells (the lengths of the diffusion pathways through
423 the polymeric matrices) in this case.

Furthermore, the diffusion of the short chain acids out of the implants into the surrounding 424 bulk fluid can lead to a decrease in pH of the latter. As it can be seen in Figure 11, decreasing 425 pH values of the release medium were indeed observed in all cases. At higher polymer 426 concentrations the "pH drops" were much more pronounced than in the case of lower PLGA 427 concentrations, irrespective of the polymer molecular weight. This can probably be attributed 428 to the fact that thicker polymer "shells" are created at high PLGA concentrations, resulting in 429 more pronounced autocatalytic effects (since the generated short chain acids more slowly 430 diffuse out and bases from the release medium more slowly diffuse in, due to the longer 431 diffusion pathways to be overcome). The potential consequences of (slight) acidifications of 432 the surrounding environment in vivo should be addressed in future studies. The fact that 433 dexamethasone is an anti-inflammatory drug might help minimizing tissue irritation, but 434 caution should be taken when speculating on these aspects based on in vitro data. 435

Comparing the dynamic changes in the pH values of the surrounding bulk fluids in the case 436 of implants based on Resomer RG 502H and Resomer RG 504H (Figure 11 a vs. 11b), it can 437 be seen that the "pH drops" occur at later time points in the case of the longer chain PLGA. 438 This can at least partially be attributed to the fact that the initial polymer molecular weight was 439 higher, thus, more time is needed to generate short chain, water-soluble acids, which can diffuse 440 out. Interestingly, the "clear pH drops" in the bulk fluid observed at higher polymer 441 concentrations (open symbols in Figures 11a,b) are followed by distinct increases in the 442 systems' dry mass loss (open symbols in Figures 12a,b): The dry mass loss nicely reflects the 443 leaching of the shorter chain (water-soluble) acids out of the implants into the release medium. 444

#### 445 **4. Conclusion**

In-situ forming PLGA-based implants offer an interesting potential for ocular 446 dexamethasone delivery. Importantly, the systems can be expected to be rather robust with 447 respect to variations in the vitreous humor volumes encountered in vivo. Depending on the 448 initial drug loading, drug saturation effects within the implants and in the surrounding aqueous 449 medium can play an important role for the control of dexamethasone release. The polymer 450 molecular weight as well as the PLGA concentration in the liquid formulations determine how 451 the macromolecules precipitate as well as the extent and rate of system swelling. These are key 452 features, being decisive for the mobility of water, drug, polymer degradation products and bases 453 within the system. For example, they affect the thickness of the polymer shell, water content of 454 455 the system and importance of local drops in the micro-pH (and, thus, autocatalysis). The inner implant structure and conditions for mass transport within the *in-situ* forming implants 456 determine polymer degradation and drug release. 457

In the future, the toxicity of the solvent NMP for the ocular tissue as well as the potential consequences of local drops in pH due to leaching of PLGA degradation products should be studied in vivo. It would also be interesting to investigate the effects of the monomer ratio (lactic acid to glycolic acid) of the PLGA as well as the impact of potential additives, altering the formation of the implants and the conditions for mass transport. Such formulation changes might be used to adjust desired release kinetics for given drugs and drug doses during specific target release periods.


#### 466 **References**

- Agossa, K., Lizambard, M., Rongthong, T., Delcourt-Debruyne, E., Siepmann, J., Siepmann,
  F., 2017. Physical key properties of antibiotic-free, PLGA/HPMC-based in-situ forming
  implants for local periodontitis treatment. Int. J. Pharm. 521, 282–293.
  https://doi.org/10.1016/j.ijpharm.2017.02.039
- Bennett, L., 2016. Other Advances in Ocular Drug Delivery, in: Addo, R.T. (Ed.), Ocular Drug
  Delivery: Advances, Challenges and Applications. Springer International Publishing,
  pp. 165–185. https://doi.org/10.1007/978-3-319-47691-9\_10
- Bisht, R., Jaiswal, J.K., Oliver, V.F., Eurtivong, C., Reynisson, J., Rupenthal, I.D., 2017.
  Preparation and evaluation of PLGA nanoparticle-loaded biodegradable lightresponsive injectable implants as a promising platform for intravitreal drug delivery. J.
  Drug Deliv. Sci. Technol. 40, 142–156. https://doi.org/10.1016/j.jddst.2017.06.006
- Bonilha, V.L., Shadrach, K.G., Rayborn, M.E., Li, Y., Pauer, G.J.T., Hagstrom, S.A.,
  Bhattacharya, S.K., Hollyfield, J.G., 2013. Retinal deimination and PAD2 levels in
  retinas from donors with age-related macular degeneration (AMD). Exp. Eye Res. 111,
- 481 71–78. https://doi.org/10.1016/j.exer.2013.03.017
- Brunner, A., Mäder, K., Göpferich, A., 1999. pH and Osmotic Pressure Inside Biodegradable
  Microspheres During Erosion1. Pharm. Res. 16, 847–853.
  https://doi.org/10.1023/A:1018822002353
- Chan, A., Leung, L.-S., Blumenkranz, M.S., 2011. Critical appraisal of the clinical utility of the
  dexamethasone intravitreal implant (Ozurdex®) for the treatment of macular edema
  related to branch retinal vein occlusion or central retinal vein occlusion. Clin.
  Ophthalmol. Auckl. NZ 5, 1043–1049. https://doi.org/10.2147/OPTH.S13775
- Chiou, G.C.Y., 2011. Pharmacological treatment of dry age-related macular degeneration
  (AMD). Taiwan J. Ophthalmol. 1, 2–5. https://doi.org/10.1016/j.tjo.2011.08.001

- Desai, K.G.H., Mallery, S.R., Schwendeman, S.P., 2008. Effect of formulation parameters on
  2-methoxyestradiol release from injectable cylindrical poly(dl-lactide-co-glycolide)
  implants. Eur. J. Pharm. Biopharm. 70, 187–198.
  https://doi.org/10.1016/j.ejpb.2008.03.007
- Ding, A.G., Schwendeman, S.P., 2008. Acidic Microclimate pH Distribution in PLGA
   Microspheres Monitored by Confocal Laser Scanning Microscopy. Pharm. Res. 25,
   2041–2052. https://doi.org/10.1007/s11095-008-9594-3
- Ding, A.G., Schwendeman, S.P., 2004. Determination of water-soluble acid distribution in
  poly(lactide-co-glycolide). J. Pharm. Sci. 93, 322–331.
  https://doi.org/10.1002/jps.10524
- Do, M.P., Neut, C., Delcourt, E., Seixas Certo, T., Siepmann, J., Siepmann, F., 2014. In situ
   forming implants for periodontitis treatment with improved adhesive properties. Eur. J.
   Pharm. Biopharm. 88, 342–350. https://doi.org/10.1016/j.ejpb.2014.05.006
- Do, M.P., Neut, C., Metz, H., Delcourt, E., Mäder, K., Siepmann, J., Siepmann, F., 2015a. Insitu forming composite implants for periodontitis treatment: How the formulation
  determines system performance. Int. J. Pharm. 486, 38–51.
  https://doi.org/10.1016/j.ijpharm.2015.03.026
- Do, M.P., Neut, C., Metz, H., Delcourt, E., Siepmann, J., Mäder, K., Siepmann, F., 2015b.
  Mechanistic analysis of PLGA/HPMC-based in-situ forming implants for periodontitis
  treatment. Eur. J. Pharm. Biopharm. 94, 273–283.
  https://doi.org/10.1016/j.ejpb.2015.05.018
- Droege, K.M., Muether, P.S., Hermann, M.M., Caramoy, A., Viebahn, U., Kirchhof, B., Fauser,
  S., 2013. Adherence to ranibizumab treatment for neovascular age-related macular
  degeneration in real life. Graefes Arch. Clin. Exp. Ophthalmol. 251, 1281–1284.
  https://doi.org/10.1007/s00417-012-2177-3

516	Edelhauser, H.F., Rowe-Rendleman, C.L., Robinson, M.R., Dawson, D.G., Chader, G.J.,
517	Grossniklaus, H.E., Rittenhouse, K.D., Wilson, C.G., Weber, D.A., Kuppermann, B.D.,
518	Csaky, K.G., Olsen, T.W., Kompella, U.B., Holers, V.M., Hageman, G.S., Gilger, B.C.,
519	Campochiaro, P.A., Whitcup, S.M., Wong, W.T., 2010. Ophthalmic Drug Delivery
520	Systems for the Treatment of Retinal Diseases: Basic Research to Clinical Applications.
521	Investig. Opthalmology Vis. Sci. 51, 5403. https://doi.org/10.1167/iovs.10-5392
522	Fredenberg, S., Wahlgren, M., Reslow, M., Axelsson, A., 2011. The mechanisms of drug
523	release in poly(lactic-co-glycolic acid)-based drug delivery systems—A review. Int. J.
524	Pharm. 415, 34-52. https://doi.org/10.1016/j.ijpharm.2011.05.049
525	Gasmi, H., Danede, F., Siepmann, J., Siepmann, F., 2015a. Does PLGA microparticle swelling
526	control drug release? New insight based on single particle swelling studies. J. Controlled
527	Release 213, 120–127. https://doi.org/10.1016/j.jconrel.2015.06.039
528	Gasmi, H., Siepmann, F., Hamoudi, M.C., Danede, F., Verin, J., Willart, JF., Siepmann, J.,
529	2016. Towards a better understanding of the different release phases from PLGA
530	microparticles: Dexamethasone-loaded systems. Int. J. Pharm., In Honour of Professor
531	Alexander T. FlorenceIn Honour of Professor Alexander T. Florence 514, 189–199.
532	https://doi.org/10.1016/j.ijpharm.2016.08.032
533	Gasmi, H., Willart, JF., Danede, F., Hamoudi, M.C., Siepmann, J., Siepmann, F., 2015b.
534	Importance of PLGA microparticle swelling for the control of prilocaine release. J. Drug
535	Deliv. Sci. Technol. 30, 123-132. https://doi.org/10.1016/j.jddst.2015.10.009
536	Ghalanbor, Z., Körber, M., Bodmeier, R., 2013. Interdependency of protein-release
537	completeness and polymer degradation in PLGA-based implants. Eur. J. Pharm.
538	Biopharm. 85, 624–630. https://doi.org/10.1016/j.ejpb.2013.03.031

- Ghazala, F., Hovan, M., Mahmood, S., 2013. Improving treatment provision of Wet AMD with
  intravitreal ranibizumab. BMJ Qual. Improv. Rep. 2, u201733.w993.
  https://doi.org/10.1136/bmjquality.u201733.w993
- Giudice, G.L., Galan, A., 2012. Basic Research and Clinical Application of Drug Delivery
  Systems for the Treatment of Age-Related Macular Degeneration.
  https://doi.org/10.5772/31524
- Grizzi, I., Garreau, H., Li, S., Vert, M., 1995. Hydrolytic degradation of devices based on
  poly(dl-lactic acid) size-dependence. Biomaterials 16, 305–311.
  https://doi.org/10.1016/0142-9612(95)93258-F
- Hamoudi-Ben Yelles, M.C., Tran Tan, V., Danede, F., Willart, J.F., Siepmann, J., 2017. PLGA 548 implants: How Poloxamer/PEO addition slows down or accelerates polymer 549 degradation Controlled Release 253. 19–29. 550 and drug release. J. https://doi.org/10.1016/j.jconrel.2017.03.009 551
- Hirota, K., Doty, A.C., Ackermann, R., Zhou, J., Olsen, K.F., Feng, M.R., Wang, Y., Choi, S.,
- 553 Qu, W., Schwendeman, A.S., Schwendeman, S.P., 2016. Characterizing release
- mechanisms of leuprolide acetate-loaded PLGA microspheres for IVIVC developmentI: In vitro evaluation. J. Controlled Release, The 14th edition of the European
- Symposium on Controlled Drug Delivery, Egmond aan Zee, The Netherlands on April
  13-15, 2016 244, 302–313. https://doi.org/10.1016/j.jconrel.2016.08.023
- Huang, J., Mazzara, J.M., Schwendeman, S.P., Thouless, M.D., 2015. Self-healing of pores in
  PLGAs. J. Controlled Release 206, 20–29.
  https://doi.org/10.1016/j.jconrel.2015.02.025
- Hughes, P.M., Olejnik, O., Chang-Lin, J.-E., Wilson, C.G., 2005. Topical and systemic drug
   delivery to the posterior segments. Adv. Drug Deliv. Rev., Drug Delivery Strategies to



- Kaur, I.P., Kakkar, S., 2014. Nanotherapy for posterior eye diseases. J. Controlled Release 193,
  100–112. https://doi.org/10.1016/j.jconrel.2014.05.031
- Kempe, S., Mäder, K., 2012. In situ forming implants an attractive formulation principle for
   parenteral depot formulations. J. Controlled Release, Drug Delivery Research in Europe
   161, 668–679. https://doi.org/10.1016/j.jconrel.2012.04.016
- Kempe, S., Metz, H., Pereira, P.G.C., Mäder, K., 2010. Non-invasive in vivo evaluation of in
  situ forming PLGA implants by benchtop magnetic resonance imaging (BT-MRI) and
- 572 EPR spectroscopy. Eur. J. Pharm. Biopharm., Imaging Techniques in Drug
  573 Development 74, 102–108. https://doi.org/10.1016/j.ejpb.2009.06.008
- Klose, D., Siepmann, F., Elkharraz, K., Krenzlin, S., Siepmann, J., 2006. How porosity and size 574 affect the drug release mechanisms from PLGA-based microparticles. Int. J. Pharm., 575 Local Controlled Delivery 314, 198–206. Drug the Brain to 576 https://doi.org/10.1016/j.ijpharm.2005.07.031 577
- Kowluru, R.A., Mishra, M., 2015. Oxidative stress, mitochondrial damage and diabetic
  retinopathy. Biochim. Biophys. Acta BBA Mol. Basis Dis. 1852, 2474–2483.
  https://doi.org/10.1016/j.bbadis.2015.08.001
- Kranz, H., Bodmeier, R., 2008. Structure formation and characterization of injectable drug
  loaded biodegradable devices: In situ implants versus in situ microparticles. Eur. J.
  Pharm. Sci. 34, 164–172. https://doi.org/10.1016/j.ejps.2008.03.004
- Kranz, H., Bodmeier, R., 2007. A novel in situ forming drug delivery system for controlled
  parenteral drug delivery. Int. J. Pharm. 332, 107–114.
  https://doi.org/10.1016/j.ijpharm.2006.09.033

- Kranz, H., Ubrich, N., Maincent, P., Bodmeier, R., 2000. Physicomechanical Properties of
  Biodegradable Poly(D,L-lactide) and Poly(D,L-lactide-co-glycolide) Films in the Dry
  and Wet States. J. Pharm. Sci. 89, 1558–1566. https://doi.org/10.1002/15206017(200012)89:12<1558::AID-JPS6>3.0.CO;2-8
- Kurz, P.A., Suhler, E.B., Flaxel, C.J., Rosenbaum, J.T., 2008. Injectable Intraocular
  Corticosteroids, in: Becker, M., Davis, J. (Eds.), Surgical Management of Inflammatory
  Eye Disease. Springer Berlin Heidelberg, pp. 5–16. https://doi.org/10.1007/978-3-54033862-8\_1
- Li, L., Schwendeman, S.P., 2005. Mapping neutral microclimate pH in PLGA microspheres. J.
- 596 Controlled Release, Proceedings of the Eight European Symposium on Controlled Drug
  597 Delivery 101, 163–173. https://doi.org/10.1016/j.jconrel.2004.07.029
- Lu, L., Garcia, C.A., Mikos, A.G., 1999. In vitro degradation of thin poly(DL-lactic-co-glycolic
  acid) films. J. Biomed. Mater. Res. 46, 236–244.
- Luan, X., Skupin, M., Siepmann, J., Bodmeier, R., 2006. Key parameters affecting the initial
  release (burst) and encapsulation efficiency of peptide-containing poly(lactide-coglycolide) microparticles. Int. J. Pharm. 324, 168–175.
  https://doi.org/10.1016/j.ijpharm.2006.06.004
- Parent, M., Clarot, I., Gibot, S., Derive, M., Maincent, P., Leroy, P., Boudier, A., 2017. Oneweek in vivo sustained release of a peptide formulated into in situ forming implants. Int.
  J. Pharm. 521, 357–360. https://doi.org/10.1016/j.ijpharm.2017.02.046
- Parent, M., Nouvel, C., Koerber, M., Sapin, A., Maincent, P., Boudier, A., 2013. PLGA in situ
  implants formed by phase inversion: Critical physicochemical parameters to modulate
  drug release. J. Controlled Release 172, 292–304.
  https://doi.org/10.1016/j.jconrel.2013.08.024

- Rodrigues, E.B., Grumann, A., Penha, F.M., Shiroma, H., Rossi, E., Meyer, C.H., Stefano, V., 611 Maia, M., Magalhaes, O., Farah, M.E., 2011. Effect of needle type and injection 612 technique on pain level and vitreal reflux in intravitreal injection. J. Ocul. Pharmacol. 613 Ther. Off. J. Assoc. Ocul. Pharmacol. Ther. 27. 197-203. 614 https://doi.org/10.1089/jop.2010.0082 615
- Rodríguez Villanueva, J., Rodríguez Villanueva, L., Guzmán Navarro, M., 2017.
  Pharmaceutical technology can turn a traditional drug, dexamethasone into a first-line
  ocular medicine. A global perspective and future trends. Int. J. Pharm. 516, 342–351.
  https://doi.org/10.1016/j.ijpharm.2016.11.053
- Schädlich, A., Kempe, S., Mäder, K., 2014. Non-invasive in vivo characterization of
  microclimate pH inside in situ forming PLGA implants using multispectral fluorescence
  imaging. J. Controlled Release 179, 52–62.
  https://doi.org/10.1016/j.jconrel.2014.01.024
- Schoenhammer, K., Boisclair, J., Schuetz, H., Petersen, H., Goepferich, A., 2010.
  Biocompatibility of an injectable in situ forming depot for peptide delivery. J. Pharm.
  Sci. 99, 4390–4399. https://doi.org/10.1002/jps.22149
- Schoenhammer, K., Petersen, H., Guethlein, F., Goepferich, A., 2009. Injectable in situ forming
  depot systems: PEG-DAE as novel solvent for improved PLGA storage stability. Int. J.
  Pharm. 371, 33–39. https://doi.org/10.1016/j.ijpharm.2008.12.019
- Schwendeman, S.P., Shah, R.B., Bailey, B.A., Schwendeman, A.S., 2014. Injectable controlled
  release depots for large molecules. J. Controlled Release, 30th Anniversary Special
  Issue 190, 240–253. https://doi.org/10.1016/j.jconrel.2014.05.057
- Siepmann, J., Elkharraz, K., Siepmann, F., Klose, D., 2005. How Autocatalysis Accelerates
   Drug Release from PLGA-Based Microparticles: A Quantitative Treatment.
   Biomacromolecules 6, 2312–2319. https://doi.org/10.1021/bm050228k

- 636 Siepmann, J., Siepmann, F., 2012. Modeling of diffusion controlled drug delivery. J. Controlled
- Release, Drug Delivery Research in Europe 161, 351–362.
  https://doi.org/10.1016/j.jconrel.2011.10.006
- Siepmann, J., Siepmann, F., 2008. Mathematical modeling of drug delivery. Int. J. Pharm.,
  Future Perspectives in Pharmaceutics Contributions from Younger Scientists 364, 328–
  343. https://doi.org/10.1016/j.ijpharm.2008.09.004
- Thakur, R.R.S., McMillan, H.L., Jones, D.S., 2014. Solvent induced phase inversion-based in
  situ forming controlled release drug delivery implants. J. Controlled Release 176, 8–23.
  https://doi.org/10.1016/j.jconrel.2013.12.020
- Toris, C.B., Yablonski, M.E., Wang, Y.-L., Camras, C.B., 1999. Aqueous humor dynamics in
  the aging human eye. Am. J. Ophthalmol. 127, 407–412. https://doi.org/10.1016/S00029394(98)00436-X
- Ueda, H., Hacker, M. c., Haesslein, A., Jo, S., Ammon, D. m., Borazjani, R. n., Kunzler, J. f.,
  Salamone, J. c., Mikos, A. g., 2007. Injectable, in situ forming poly(propylene
  fumarate)-based ocular drug delivery systems. J. Biomed. Mater. Res. A 83A, 656–666.
  https://doi.org/10.1002/jbm.a.31226
- <sup>652</sup> Urtti, A., 2006. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv.
- 653 Drug Deliv. Rev., Ocular Drug Delivery 58, 1131–1135.
  654 https://doi.org/10.1016/j.addr.2006.07.027
- Wan, T.-T., Li, X.-F., Sun, Y.-M., Li, Y.-B., Su, Y., 2015. Recent advances in understanding
  the biochemical and molecular mechanism of diabetic retinopathy. Biomed.
  Pharmacother. 74, 145–147. https://doi.org/10.1016/j.biopha.2015.08.002
- Wilson, C.G., Tan, L.E., Mains, J., 2011. Principles of Retinal Drug Delivery from Within the
  Vitreous, in: Kompella, U.B., Edelhauser, H.F. (Eds.), Drug Product Development for

- the Back of the Eye, AAPS Advances in the Pharmaceutical Sciences Series. Springer
  US, pp. 125–158.
- Wykoff, C.C., Croft, D.E., Brown, D.M., Wang, R., Payne, J.F., Clark, L., Abdelfattah, N.S.,
  Sadda, S.R., 2015. Prospective Trial of Treat-and-Extend versus Monthly Dosing for
  Neovascular Age-Related Macular Degeneration: TREX-AMD 1-Year Results.
  Ophthalmology 122, 2514–2522. https://doi.org/10.1016/j.ophtha.2015.08.009
- Yasin, M.N., Svirskis, D., Seyfoddin, A., Rupenthal, I.D., 2014. Implants for drug delivery to
  the posterior segment of the eye: A focus on stimuli-responsive and tunable release
  systems. J. Controlled Release 196, 208–221.
  https://doi.org/10.1016/j.jconrel.2014.09.030
- Ying, L., Tahara, K., Takeuchi, H., 2013. Drug delivery to the ocular posterior segment using
  lipid emulsion via eye drop administration: Effect of emulsion formulations and surface
  modification. Int. J. Pharm. 453, 329–335.
  https://doi.org/10.1016/j.ijpharm.2013.06.024
- Zaki, W.M.D.W., Zulkifley, M.A., Hussain, A., Halim, W.H.W.A., Mustafa, N.B.A., Ting,
   L.S., 2016. Diabetic retinopathy assessment: Towards an automated system. Biomed.
- 676 Signal Process. Control 24, 72–82. https://doi.org/10.1016/j.bspc.2015.09.011
- 677

#### 678 Web references

- http://eligard.com, accessed on 30 June 2018
- 680 https://iluvien.com, accessed on January 30 2018
- 681 https://www.merck-animal-health-usa.com/product/cattle/Nuflor-Injectable-Solution/1,
- 682 accessed on 30 June 2018
- http://www.retisert.com, accessed on January 30 2018
- https://www.zoetisus.com/products/dogs/doxirobe-gel.aspx, accessed on 30 June 2018

#### 685 Figure legends

686


Fig. 1. Macroscopic pictures of implants formed *in-situ* upon exposure to phosphate buffer
pH 7.4 before and after freeze drying (surfaces and cross-sections). The formulations
contained 0.75 % dexamethasone and 30 % PLGA 502H. The volume of the release
medium was 2.25 mL (left column) or 4.5 mL (right column). The pictures were taken
after 3 d. The dashed regions highlight the hollow cores of the implants.

- Fig 2. Impact of the volume of the release medium (phosphate buffer pH 7.4) on: a) drug
  release, and b) the dynamic changes in the water/NMP content of *in-situ* forming
  implants. The formulations contained 0.75 % dexamethasone and 30 % PLGA 502H.
  Mean values +/- standard deviation are indicated (n=3).
- Fig. 3. Impact of the initial drug loading (indicated in the diagrams) of *in-situ* forming implants on the resulting: a) drug release kinetics, b) dynamic changes in the wet mass and c) dynamic changes in the water/NMP content of the systems after exposure to phosphate buffer pH 7.4. The formulations contained 30 % PLGA 502H. The volume of the release medium was 2.25 mL. Mean values +/- standard deviation are indicated (n=3).
- Fig. 4. Impact of the sampling frequency during the drug release measurements on: a) the cumulative relative amount of drug released, and b) the degree of saturation of the withdrawn samples. The formulations contained 7.5 % dexamethasone and 30 %
  PLGA 502H. The volume of the release medium was 4.5 mL. Mean values +/standard deviation are indicated (n=3).
- Fig. 5. Importance of the polymer molecular weight of the PLGA (Resomer 502H vs. 504H) for: a) drug release, b) the dynamic changes in the wet mass, and c) the dynamic changes in the water/NMP content from/of implants formed *in-situ* upon exposure to phosphate buffer pH 7.4. The formulations contained 0.25 % dexamethasone and

- 30 % PLGA. The volume of the release medium was 2.25 mL. Mean values +/standard deviation are indicated (n=3).
- Fig. 6. Impact of the PLGA concentration in the formulation on the resulting dexamethasone
  release kinetics from *in-situ* formed implants upon exposure to 2.25 mL phosphate
  buffer pH 7.4: a) PLGA 502H and b) PLGA 504H. The drug content was 0.25 %.
  Mean values +/- standard deviation are indicated (n=3).
- Fig. 7. Macroscopic pictures of cross-sections of freeze-dried *in-situ* formed implants after 3 d exposure to 2.25 mL phosphate buffer 7.4. The formulations contained 0.25 % dexamethasone and 30 % or 45 % PLGA 502H or 15 % or 30 % PLGA 504H. The cross-sections were obtained by manual breaking. All implants were hollow, the cavities are highlighted by the dashed areas.
- Fig. 8. Impact of the PLGA concentration in the formulation on the dynamic changes in the wet mass of implants formed *in-situ* upon exposure to 2.25 mL phosphate buffer pH 7.4: a) PLGA 502H and b) PLGA 504H. The formulations contained 0.25 % dexamethasone. Mean values +/- standard deviation are indicated (n=3).
- Fig. 9. Effects of the PLGA concentration in the formulation on the dynamic changes in the water/NMP content of implants formed *in-situ* upon exposure to 2.25 mL phosphate buffer pH 7.4: a) PLGA 502H and b) PLGA 504H. The formulations contained 0.25 % dexamethasone. Mean values +/- standard deviation are indicated (n=3).
- Fig. 10. Impact of the PLGA concentration in the formulation on PLGA degradation in
  implants formed *in-situ* upon exposure to 2.25 mL phosphate buffer pH 7.4: a) PLGA
  502H and b) PLGA 504H. The formulations contained 0.25 % dexamethasone. Mean
  values +/- standard deviation are indicated (n=3).
- Fig. 11. Effects of the PLGA concentration in the formulation on the dynamic changes in the pH of the release medium surrounding implants formed *in-situ* upon exposure to

736		2.25 mL phosphate buffer pH 7.4: a) PLGA 502H and b) PLGA 504H. The
737		formulations contained 0.25 % dexamethasone. Mean values +/- standard deviation
738		are indicated (n=3).
739	Fig. 12.	Impact of the PLGA concentration in the formulation on the dry mass loss of implants
740		formed <i>in-situ</i> upon exposure to 2.25 mL phosphate buffer pH 7.4: a) PLGA 502H
741		and b) PLGA 504H. The formulations contained 0.25 % dexamethasone. Mean values
742		+/- standard deviation are indicated (n=3).






























Figure 2




Figure 3






Figure 4




Figure 5
















Figure 6




Figure 7






Figure 8




Figure 9


















Figure 10




Figure 11







. . . . .








Figure 12